SIRIUS-SLE LTE: Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). (clinicaltrials.gov) - Oct 1, 2026 - P3 | N=550 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2032 ➔ Oct 2034 | Trial primary completion date: Apr 2030 ➔ Apr 2034
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|